The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Sickle Cell Disease Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Kidney function changes after 12 months of voxelotor treatment in sickle cell disease
In this video, Gonzalo De Luna, MD, Henri-Mondor University Hospital, Créteil, France, discusses renal outcomes from the HEMOPROVE study (NCT05199766), which evaluated the effects of voxelotor treatment in patients with sickle cell disease (SCD). Dr De Luna notes that 12 months of treatment with voxelotor decreased measured glomerular filtration rate (mGFR) in patients with glomerular hyperfiltration and increased it in patients with reduced mGFR at baseline. Additionally, improvements in mGFR were correlated with a decrease in plasma oxyhemoglobin. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Thanks again for letting me show this result concerning our Phase II trial, HEMOPROVE trial. You know that sickle cell nephropathy is a major complication of sickle cell disease. And our study assesses voxelotor’s impact on renal function after 12 months of treatment. And 19 patients were evaluable and receiving voxelotor at doses of 1,500 milligrams daily. And the hemoglobin increased from 7...
Thanks again for letting me show this result concerning our Phase II trial, HEMOPROVE trial. You know that sickle cell nephropathy is a major complication of sickle cell disease. And our study assesses voxelotor’s impact on renal function after 12 months of treatment. And 19 patients were evaluable and receiving voxelotor at doses of 1,500 milligrams daily. And the hemoglobin increased from 7.2 to 9 grams per deciliter, and plasma oxyhemoglobin decreased significantly, indicating a reduction of hemolysis.
The renal outcomes vary by the baseline status of our patients. We have the first group, the hyperfiltration group, six patients, defined by a measured GFR, more than 134 milliliters per minute. And in this group, the measured GFR decreased from 150 to 120 after 12 months of treatment. We have a second group, the hypofiltration group, seven patients, defined by measured GFR below 90 milliliters per minute, and in this group, the measured GFR improved from 66 milliliters per minute at baseline to 85 milliliters per minute at the last follow-up after 12 months of treatment. The normal filtration group remained stable.
Though in conclusion, improvements in measured GFR were correlated in this work with reduced plasma oxyhemoglobin. Albuminuria and uric acid concentration ability showed no significant change in this cohort, and voxelotor improved the renal function for us in this patient with abnormal measured GFR, likely through hemolysis reduction. Though we think that long-term studies are needed to confirm renal protection when we use this kind of anti-sickling approach.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
